These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21067398)

  • 1. Myocardial fibrosis in hypertrophic cardiomyopathy.
    Kaye DM; Iles L; Taylor AJ
    N Engl J Med; 2010 Nov; 363(20):1971; author reply 1971. PubMed ID: 21067398
    [No Abstract]   [Full Text] [Related]  

  • 2. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.
    Ho CY; López B; Coelho-Filho OR; Lakdawala NK; Cirino AL; Jarolim P; Kwong R; González A; Colan SD; Seidman JG; Díez J; Seidman CE
    N Engl J Med; 2010 Aug; 363(6):552-63. PubMed ID: 20818890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy.
    Yang C; Qiao S; Song Y; Liu Y; Tang Y; Deng L; Yuan J; Hu F; Yang W
    Cardiovasc Pathol; 2019; 43():107150. PubMed ID: 31639652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial late gadolinium enhancement is associated with raised serum amino-terminal propeptide of type III collagen concentrations in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha tropomyosin gene: magnetic resonance imaging study.
    Sipola P; Peuhkurinen K; Lauerma K; Husso M; Jääskeläinen P; Laakso M; Aronen HJ; Risteli J; Kuusisto J
    Heart; 2006 Sep; 92(9):1321-2. PubMed ID: 16908707
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy.
    Maron MS; Chan RH; Kapur NK; Jaffe IZ; McGraw AP; Kerur R; Maron BJ; Udelson JE
    Am J Med; 2018 Jul; 131(7):837-841. PubMed ID: 29604289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of atenolol on NT-proBNP and troponin in asymptomatic cats with severe left ventricular hypertrophy because of hypertrophic cardiomyopathy: a pilot study.
    Jung SW; Kittleson MD
    J Vet Intern Med; 2011; 25(5):1044-9. PubMed ID: 21781160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene.
    Magga J; Sipola P; Vuolteenaho O; Risteli J; Jääskeläinen P; Peuhkurinen K; Kuusisto J
    Am J Cardiol; 2008 Apr; 101(8):1185-90. PubMed ID: 18394456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
    Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardial fibrosis and the functional activity of leukocytes in patients with essential arterial hypertension].
    Moiseeva OM; Aleshina GM; Ivanova TG; Kokriakov VN; Shliakhto EV
    Vestn Ross Akad Med Nauk; 2006; (8):3-7. PubMed ID: 17002017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procollagen type III amino terminal peptide and myocardial fibrosis: A study in hypertensive patients with and without left ventricular hypertrophy.
    dos Santos Moreira C; Serejo F; Alcântara P; Ramalhinho V; Braz Nogueira J
    Rev Port Cardiol; 2015 May; 34(5):309-14. PubMed ID: 25958256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systolic and diastolic myocardial mechanics in hypertrophic cardiomyopathy and their link to the extent of hypertrophy, replacement fibrosis and interstitial fibrosis.
    Nucifora G; Muser D; Gianfagna P; Morocutti G; Proclemer A
    Int J Cardiovasc Imaging; 2015 Dec; 31(8):1603-10. PubMed ID: 26210792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the utility of circulating biomarkers of collagen synthesis in hypertrophic cardiomyopathy.
    Ellims AH; Taylor AJ; Mariani JA; Ling LH; Iles LM; Maeder MT; Kaye DM
    Circ Heart Fail; 2014 Mar; 7(2):271-8. PubMed ID: 24481111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collagen peptides, interstitial remodelling and sudden cardiac death in hypertrophic cardiomyopathy.
    Vílchez JA; Hernández-Romero D; Ruiz-Espejo F; Garcia-Honrubia A; Valdés M; Martínez-Hernández P; Marín F
    Clin Chem Lab Med; 2011 Sep; 49(9):1569-71. PubMed ID: 21663563
    [No Abstract]   [Full Text] [Related]  

  • 15. Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy.
    Kawasaki T; Sakai C; Harimoto K; Yamano M; Miki S; Kamitani T
    Am J Cardiol; 2013 Sep; 112(6):867-72. PubMed ID: 23746480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum versus Imaging Biomarkers in Friedreich Ataxia to Indicate Left Ventricular Remodeling and Outcomes.
    Mehta N; Chacko P; Jin J; Tran T; Prior TW; He X; Agarwal G; Raman SV
    Tex Heart Inst J; 2016 Aug; 43(4):305-10. PubMed ID: 27547137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial myocardial fibrosis in hypertrophic cardiomyopathy demonstrated by 18F-fluoro-deoxyglucose positron emission tomography and multislice computed tomography.
    Funabashi N; Nakagawa K; Komuro I
    Int J Cardiol; 2006 Feb; 107(2):284-6. PubMed ID: 15913811
    [No Abstract]   [Full Text] [Related]  

  • 18. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome progressing to ventricular dilation.
    Shibata M; Yamakado T; Imanaka-Yoshida K; Isaka N; Nakano T
    Am Heart J; 1996 Jun; 131(6):1223-5. PubMed ID: 8644606
    [No Abstract]   [Full Text] [Related]  

  • 19. [Myocardial fibrosis in hypertrophic cardiomyopathy].
    Payá E; Marín F; Feliu E
    Rev Esp Cardiol; 2005 May; 58(5):585-6. PubMed ID: 15899200
    [No Abstract]   [Full Text] [Related]  

  • 20. Ventricular fibrogenesis activity assessed by serum levels of procollagen type III N-terminal amino peptide during the staged Fontan procedure.
    Sugimoto M; Saiki H; Tamai A; Seki M; Inuzuka R; Masutani S; Senzaki H
    J Thorac Cardiovasc Surg; 2016 Jun; 151(6):1518-26. PubMed ID: 26926385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.